Home > Insider Trading > Filing (0001144204-16-076291)

Filing Details

Accession Number:: 0001144204-16-076291
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-01-20 16:30:58
Reporting Period:: 2016-01-15

Filing Date:: 2016-01-20
Accepted Time:: 2016-01-20 16:30:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235007	Endocyte Inc	ECYT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1267959	A Fred Middleton	400 South El Camino Real Ste 1200 San Mateo CA 94402-1708		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-01-15	20,000	$2.80	190,999	No	4	P	Direct
Common Stock	Acquisiton	2016-01-19	10,000	$2.79	200,999	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,017,304	Indirect	By Sanderling Venture Partners V, L.P.
Common Stock	831,461	Indirect	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock	267,491	Indirect	By Sanderling Venture Partners V Co-Investment Fund, L.P.
Common Stock	249,148	Indirect	By Sanderling V Biomedical, L.P.
Common Stock	162,170	Indirect	By Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock	113,315	Indirect	By Sanderling V Limited Partnership
Common Stock	100,828	Indirect	By Sanderling V Beteiligungs GmbH & Co. KG
Common Stock	10,049	Indirect	By Sanderling VI Limited Partnership
Common Stock	8,434	Indirect	By Sanderling VI Beteiligungs GmbH & Co. KG
Common Stock	785,417	Indirect	By Sanderling V Strategic Exit Fund, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.84, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
Fred Middleton is a managing director of Middleton, McNeil & Mills Associates V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling VI Limited Partnership and Sanderling V Strategic Exit Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling V Strategic Exit Fund, L.P. and Sanderling VI Limited Partnership.
Fred Middleton is a managing director of Middleton, McNeil & Mills Associate V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners V Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares of record by Sanderling Venture Partners V Co-Investment Fund, L.P.